Rhumbline Advisers Has $575,000 Stake in Ra Pharmaceuticals Inc (NASDAQ:RARX)

Rhumbline Advisers increased its stake in shares of Ra Pharmaceuticals Inc (NASDAQ:RARX) by 23.9% during the first quarter, according to the company in its most recent filing with the SEC. The fund owned 25,685 shares of the company’s stock after acquiring an additional 4,960 shares during the period. Rhumbline Advisers’ holdings in Ra Pharmaceuticals were worth $575,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors also recently modified their holdings of RARX. RA Capital Management LLC increased its holdings in shares of Ra Pharmaceuticals by 26.1% during the 4th quarter. RA Capital Management LLC now owns 4,858,260 shares of the company’s stock valued at $33,963,000 after acquiring an additional 1,006,452 shares during the last quarter. BlackRock Inc. increased its holdings in shares of Ra Pharmaceuticals by 29.0% during the 4th quarter. BlackRock Inc. now owns 2,645,261 shares of the company’s stock valued at $48,142,000 after acquiring an additional 595,328 shares during the last quarter. Sectoral Asset Management Inc increased its holdings in shares of Ra Pharmaceuticals by 129.3% during the 4th quarter. Sectoral Asset Management Inc now owns 799,612 shares of the company’s stock valued at $14,553,000 after acquiring an additional 450,900 shares during the last quarter. Candriam Luxembourg S.C.A. increased its holdings in shares of Ra Pharmaceuticals by 102.1% during the 4th quarter. Candriam Luxembourg S.C.A. now owns 879,000 shares of the company’s stock valued at $15,997,000 after acquiring an additional 444,000 shares during the last quarter. Finally, FMR LLC increased its holdings in shares of Ra Pharmaceuticals by 454.2% during the 4th quarter. FMR LLC now owns 413,389 shares of the company’s stock valued at $7,524,000 after acquiring an additional 338,801 shares during the last quarter. 94.97% of the stock is currently owned by institutional investors and hedge funds.

A number of research firms have issued reports on RARX. Zacks Investment Research lowered Ra Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Wednesday. BidaskClub lowered Ra Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Tuesday. Svb Leerink began coverage on Ra Pharmaceuticals in a report on Wednesday, May 22nd. They issued an “outperform” rating and a $33.00 target price on the stock. Leerink Swann began coverage on Ra Pharmaceuticals in a report on Wednesday, May 22nd. They issued an “outperform” rating and a $23.30 target price on the stock. Finally, SunTrust Banks raised their target price on Ra Pharmaceuticals to $42.00 and gave the company a “buy” rating in a report on Friday, May 17th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and ten have given a buy rating to the company’s stock. Ra Pharmaceuticals presently has an average rating of “Buy” and an average target price of $37.23.

RARX traded up $0.05 during midday trading on Wednesday, reaching $19.93. The company’s stock had a trading volume of 22,342 shares, compared to its average volume of 416,943. The firm has a market capitalization of $846.06 million, a P/E ratio of -9.67 and a beta of 0.79. The company has a quick ratio of 20.10, a current ratio of 20.10 and a debt-to-equity ratio of 0.02. Ra Pharmaceuticals Inc has a twelve month low of $8.01 and a twelve month high of $27.68.

Ra Pharmaceuticals (NASDAQ:RARX) last released its earnings results on Thursday, May 9th. The company reported ($0.45) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.47) by $0.02. As a group, analysts anticipate that Ra Pharmaceuticals Inc will post -1.98 earnings per share for the current year.

ILLEGAL ACTIVITY WARNING: This piece of content was reported by Sports Perspectives and is the property of of Sports Perspectives. If you are accessing this piece of content on another site, it was illegally stolen and republished in violation of US and international copyright & trademark legislation. The legal version of this piece of content can be viewed at https://sportsperspectives.com/2019/06/12/rhumbline-advisers-has-575000-stake-in-ra-pharmaceuticals-inc-nasdaqrarx.html.

Ra Pharmaceuticals Company Profile

Ra Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of diseases caused by excessive or uncontrolled activation of the complement system. The company's peptide chemistry platform enables the production of synthetic macrocyclic peptides that combine the diversity and specificity of antibodies with the pharmacological properties of small molecules.

Featured Story: Why is the price-sales ratio important?

Want to see what other hedge funds are holding RARX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ra Pharmaceuticals Inc (NASDAQ:RARX).

Institutional Ownership by Quarter for Ra Pharmaceuticals (NASDAQ:RARX)

Receive News & Ratings for Ra Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ra Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.